Top Questions in Alcohol-Associated Liver Disease: A Community Conversation on Glucagon-like Peptide-1 Receptor Agonists, Sex, and Integrated Care

Alcohol-associated liver disease (ALD) is evolving faster than our clinical paradigms. Women are developing severe ALD at unprecedented rates despite lower alcohol consumption levels. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer tantalizing dual benefits for cravings and steatosis. Traditional screening tools may miss high-functioning patients with metabolic risk. This rapid-fire community conversation tackles 4 critical questions hepatologists face daily, moving from, "Is there a safe drinking limit?" to, "Why do systemic barriers prevent integrated alcohol use disorder care?" Four expert discussants present emerging data and clinical realities in focused segments, followed by an open panel discussion and audience questions and answers for crosscutting synthesis.